Compare CLPS & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLPS | CCEL |
|---|---|---|
| Founded | 2005 | 1989 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Managed Health Care |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.3M | 29.6M |
| IPO Year | 2017 | 2022 |
| Metric | CLPS | CCEL |
|---|---|---|
| Price | $0.89 | $3.53 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 19.4K | 7.5K |
| Earning Date | 03-06-2026 | 04-14-2026 |
| Dividend Yield | ★ 14.61% | 4.09% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $25,384,279.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $350.01 |
| Revenue Growth | N/A | ★ 9.76 |
| 52 Week Low | $0.80 | $2.72 |
| 52 Week High | $1.88 | $5.76 |
| Indicator | CLPS | CCEL |
|---|---|---|
| Relative Strength Index (RSI) | 40.67 | 49.99 |
| Support Level | $0.84 | $3.18 |
| Resistance Level | $0.99 | $3.57 |
| Average True Range (ATR) | 0.06 | 0.30 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 11.80 | 22.73 |
CLPS Inc. is an IT consulting and solutions provider serving international clients in the banking, wealth management, e-commerce, and automotive sectors. The company drives digital transformation using AI, cloud computing, and big data, offering IT consulting, customized solutions, virtual banking training, recruitment, professional training, and software services. It operates mainly in two segments: IT services, which generate the majority of its revenue, and academic education services. The company has a presence in Hong Kong, Singapore, Mainland China, India, Malaysia, and Japan, with the majority of its revenue coming from Mainland China.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.